Acathia Capital Increases Stake in Swedish Savings Platform Futur
3.12.2024 17:46:00 CET | Business Wire | Press release
Acathia Capital has signed its second GP-led secondary transaction thereby increasing its stake in Futur, Sweden's leading pension and savings platform. For this investment Acathia Capital is backed by Montana Capital Partners, a global private equity secondaries investment manager and part of PGIM, the global investment management business of Prudential Financial, Inc. (NYSE: PRU). MCP serves as the main investor in this transaction, alongside a German insurance company.
Since 2019, Acathia Capital and Nordic private equity manager Polaris Private Equity have jointly lead-managed the investment in Futur alongside 3 passive co-investors. In this transaction, Acathia Capital acquired shares from one co-investor through its new vehicle Fjord Pension SCS.
The transaction is another milestone in the journey of Acathia Capital’s successful investment strategy of full conviction investments on a deal-by-deal basis in the financial services sector. Acathia now manages over EUR 300 million AuM.
Futur exemplifies the power of digitalization in the savings market. The company has redefined Sweden’s life insurance market through cost and service leadership, gaining significant market share through end-to-end digitalization and full scalability.
Thanks to its fully digitalized operations, Futur benefits from unique competitive advantages, including:
- Best-in-class partner satisfaction
- Unrivalled cost efficiency
- Leading product innovation capability
Dr. Thomas Schmitt, Managing Partner at Acathia Capital, remarked: “Since our investment in Futur began in 2019, Futur has tripled its assets under management to SEK 240bn. and more than quadrupled its profits, establishing itself as a market leader in Sweden.”
Torgny Johansson, CEO of Futur, says: “We stick to our strategy, to be independent and focus on simplicity for our partners as well as our joint customers.”
About Futur
Futur is a technology-powered pension and savings platform with a life insurance license. It offers long-term savings and insurance cover, with a particular focus on occupational pension and capital insurance. The platform offers leading efficiency, simplicity and access to an independent, quality proofed fund offering. Futur administers over SEK 240bn AuM in 2024 in the form of unit-linked insurance policies.
About Acathia Capital
Acathia Capital specializes in investments in fully regulated insurers and banks across Europe and manages over EUR 300 million in investments for German and Swiss institutional investors. With a track record of creating top-quartile returns for investors, Acathia Capital drives transformative growth in its portfolio companies.
The closing of the transaction is subject to approval of the Swedish Financial Supervisory Authority.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241203919861/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom